

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1-16. (Canceled)

17. (Currently Amended) A method of treating an ~~infectious disease~~ or allergic disorder in a mammal comprising administering to said mammal a therapeutically effective amount of a TCCR agonist antibody or TCCR binding fragment thereof.

18-19. (Canceled)

20. (Previously Presented) The method of claim 17, wherein the allergic disorder is selected from the group consisting of: asthma, allergic rhinitis, atopic dermatitis, and vernal conjunctivitis.

21-22. (Canceled)

23. (Previously Presented) The method of claim 17, wherein the agonist antibody is a monoclonal antibody or fragment thereof.

24. (Previously Presented) The method of claim 17, wherein the agonist antibody is a humanized antibody or fragment thereof.

25. (Previously Presented) The method of claim 17, wherein the agonist antibody or fragment is a single-chain antibody, linear antibody, Fab, Fab', F(ab)', Fv, or diabody.

26-34. (Canceled)

35. (Previously Presented) The method of claim 17, wherein said agonist is administered in combination with a cytotoxic agent, cytokine, anti-cancer agent, or growth inhibitory agent.